Captive Insurance in Abbott Park, Illinois 60064

Attention: open in a new window. PDFPrintE-mail

Capstone Insurance Management, Ltd. (CIMA), which is both a licensed captive insurance manager and a licensed company manager, facilitates captive planning whether done in the U.S. or offshore. Today, CIMA is among the largest and most active captive managers in Abbott Park, Illinois 60064. To get more information, please fill out the form below.

 


 

Local News

Abbott Park Illinois - Yahoo! News Search Results

Abbott Park Illinois - Yahoo! News Search Results

  • — Press Release

       (Tuesday, 08 May 2012 05:09)

    Abbott Park, Illinois (NYSE: ABT) and Aarhus, Denmark, — Abbott and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.

  • — Abbott Laboratories to pay $1.6 billion over misbranding drug

       (Monday, 07 May 2012 18:29)

    Abbott Laboratories has pleaded guilty and agreed to pay $1.6 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote, the U.S. Justice Department said Monday.

  • — Abbott Agrees To Pay $1.6 Bln. In Depakote Settlement

       (Monday, 07 May 2012 14:29)

    Drug maker Abbott Laboratories (ABT) pleaded guilty and agreed to pay a total of $1.6 billion to settle the criminal and civil claims that arose from past unlawful promotion of neurologic drug Depakote.

  • — Abbott Labs Settles Depakote Investigation For $1.6 Billion

       (Monday, 07 May 2012 13:35)

    Medical device and drugmaker Abbott Laboratories (NYSE: ABT) said it will pay $1.6 billion to settle federal and state claims regarding illegal off-label sales and marketing of its neurologic medication Depakote.

  • — Abbott to Pay $1.6 Billion to Settle Depakote Drug Allegations

       (Monday, 07 May 2012 13:07)

    Abbott Laboratories (ABT) said it reached an agreement to pay $1.6 billion to settle federal and state claims resulting from an investigation into its epilepsy medication Depakote, the second-largest drug-marketing settlement in U.S. history.